PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers
Status:
Not yet recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to obtain pharmacokinetics, safety and tolerability data after
single administrations of CHF6001 in subjects with mild, moderate and severe renal impairment
as well as healthy volunteers under the same setting.